Objectif Recent advances in genomics, molecular science, and big data are changing the way we define and target diseases, but drug discovery is still a time-consuming, expensive and risky process. Genome Biologics provides a unique combination of tools – GENIMAPS and GENISYST – to provide an integrated platform, with a disruptive effect on the time, cost and risk of drug discovery and pre-clinical trial development.GENISYST uses a unique transgenic methodology to allow up to 50 genes to be expressed in one animal, directly in target tissue, without affecting the genome. This methodology removes the need for breeding, radically reducing the number of animals needed to make a transgenic animal model by a factor of 100, and enables transgenic large animal models, a current commercial gap in the market. The toolkit reduces the time to prepare animal models, and the cost of drug discovery and pre-clinical trials, by an order of magnitude. The impact of this is cheaper, more rapidly developed, drugs, with a greater target to market success rate.GENIMAPS combines big data, AI and a unique multi-omics approach to make rapid and precise matches between disease indicators and compound behaviours, allow rapid identification of targets, genetic expression, and compound matches. As well as precision medicine, GENIMAPS also allows the rapid evaluation of an existing pipeline, allowing repositioning of a company’s existing, FDA approved assets (or orphan drugs) – increasing the return on public and private investment. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverynatural sciencescomputer and information sciencesdata sciencebig datamedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health scienceshealth sciencespersonalized medicinenatural sciencesbiological sciencesgeneticsgenomes Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Thème(s) EIC-SMEInst-2018-2020 - SME instrument Appel à propositions H2020-EIC-SMEInst-2018-2020 Voir d’autres projets de cet appel Sous appel H2020-SMEInst-2018-2020-2 Régime de financement SME-2 - SME instrument phase 2 Coordinateur GENOME BIOLOGICS UG Contribution nette de l'UE € 2 425 325,00 Adresse DANZIGER WEG 17 61476 KRONBERG IM TAUNUS Allemagne Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Hessen Darmstadt Hochtaunuskreis Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 3 464 750,00
